Dapagliflozin in Myocardial Infarction without Diabetes or Heart Failure

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Related collections

Most cited references 31

Record: found
Abstract: found
Article: not found

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

Bernard Zinman, Christoph Wanner, John M. Lachin … (2015)

The effects of empagliflozin, an inhibitor of sodium-glucose cotransporter 2, in addition to standard care, on cardiovascular morbidity and mortality in patients with type 2 diabetes at high cardiovascular risk are not known.

0 comments Cited 2560 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: not found
Article: not found

2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation

Héctor Bueno, Borja Ibanez, Stefan James … (2017)

0 comments Cited 2430 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

John J.V. McMurray, Scott D. Solomon, Silvio E Inzucchi … (2020)

In patients with type 2 diabetes, inhibitors of sodium-glucose cotransporter 2 (SGLT2) reduce the risk of a first hospitalization for heart failure, possibly through glucose-independent mechanisms. More data are needed regarding the effects of SGLT2 inhibitors in patients with established heart failure and a reduced ejection fraction, regardless of the presence or absence of type 2 diabetes.

0 comments Cited 2051 times – based on 0 reviews      Review now

Bookmark

All references

Author and article information

Journal

Title: NEJM Evidence

Abbreviated Title: NEJM Evidence

Publisher: Massachusetts Medical Society

ISSN (Print): 2766-5526

Publication date (Electronic): November 11 2023

Affiliations

[1 ]Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden

[2 ]Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden

[3 ]Department of Cardiology, Clinical Sciences, Lund University, Skåne University Hospital, Lund, Sweden

[4 ]Cardiovascular Research Unit, Division of Clinical Medicine, School of Medicine and Population Health, University of Sheffield, Sheffield, United Kingdom

[5 ]NIHR Sheffield Biomedical Research Centre, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom

[6 ]Division of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas

[7 ]Division of Cardiology, Parkland Health and Hospital System, Dallas

[8 ]National Institute for Cardiovascular Outcomes Research (NICOR), NHS Arden & GEM Commissioning Support Unit, Leicester, United Kingdom

[9 ]Department of Medical Sciences, Clinical Epidemiology, Uppsala University, Uppsala, Sweden

[10 ]Academic Cardiovascular Unit, The James Cook University Hospital, South Tees NHS FT, Middlesbrough, United Kingdom

[11 ]Population Health Science Institute, Newcastle University, Newcastle, United Kingdom

[12 ]Thoracic Center, Blekinge Hospital, Karlskrona, Sweden

[13 ]Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom

[14 ]Department of Cardiology, University Hospital Hairmyres, East Kilbride, United Kingdom

[15 ]Department of Clinical Science and Education, Division of Cardiology, Karolinska Institutet, Södersjukhuset, Stockholm

[16 ]Department of Interventional Cardiology, Royal Papworth Hospital, Cambridge, United Kingdom

[17 ]William Harvey Research Institute, Barts & The London Faculty of Medicine & Dentistry, Queen Mary University of London, London

[18 ]Department of Cardiology, St. Bartholomew’s Hospital, West Smithfield, London

[19 ]Lincolnshire Heart Centre, United Lincolnshire Hospitals NHS Trust, Lincoln, United Kingdom

[20 ]School of Life Sciences, University of Lincoln, Lincoln, United Kingdom

[21 ]Department of Medicine, South Älvsborg Hospital, Borås, Sweden

[22 ]Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden

[23 ]Late-Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals Research and Development, AstraZeneca, Gothenburg, Sweden

[24 ]Institute of Cardiovascular Sciences, University College London, London

Article

DOI: 10.1056/EVIDoa2300286

PubMed ID: 38320489

SO-VID: a5625049-60b7-4791-a226-8364fc6bb3e6

History

Data availability:

Comments

Comment on this article

scite_

Cited by 21

See all cited by

Most referenced authors 1,196

See all reference authors

Dapagliflozin in Myocardial Infarction without Diabetes or Heart Failure

Read this article at

Related collections

University of Westminster Press

Most cited references 31

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

Author and article information

Journal

Affiliations

Article

History

Comments

Comment on this article

Similar content 2,915

Cited by 21

Most referenced authors 1,196